Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company's product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical trials for the treatment of hematologic malignancies, as well as Phase I clinical trial for treating solid tumors; and AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors. In addition, the company is involved in developing AG-348, an potent activator that is in Phase II DRIVE PK clinical trial; and AG-519 potent activator that are in Phase I clinical trial for treating patients with pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and with Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene thestreet.com The first targeted blood cancer drug from Agios Pharmaceuticals (AGIO) will be submitted for approval in the U.S. by the end of the year, faster than investors expected. Celgene (CELG) , which owns the rights to the Agios drug, known as AG-221, under an existing partnership, will be in charge of filing the new drug application for the treatment of patients with relapsed or refractory acute myeloid leukemia, or AML, caused by a mutated protein known as IDH2. Agios disclosed the AG-221 approval submission plan in an 8-K filing to the Securities and Exchange Commission on Wednesday morning. Celgene plans to elaborate on its AG-221 plans later today during a presentation at a health care investor conference, the Agios 8-K said.
Analyst Upgrade/Downgrade Update Brokerage firm: Needham Change: Coverage Initiated Previous Rating: N/A Current Rating: Buy Previous Price Target: N/A Current Price Target: $60
Shares of Agios Pharmaceuticals ($AGIO) may come under pressure after the company announced it is offering to sell up to 4.5 million shares of its common stock in an underwritten public offering.
